Revolutionizing mRNA for Life

Pierre Kemula, Chief Financial Officer
SVB Leerink 10th Annual Global Healthcare Conference, February 2021
Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
CureVac at a Glance

**PIONEERS IN MEDICAL MRNA APPLICATIONS**
- Founded in 2000
- Headquartered in Tübingen
- 511 employees*
- Nasdaq listed

**UNIQUE MRNA TECHNOLOGY**
- Unmodified mRNA
- Balanced immune activation
- Low dose activity

**DEEP CLINICAL PIPELINE**
- Prophylactic Vaccines
- Immuno-oncology
- Protein Therapies

**MANUFACTURING EXPERTISE**
- 3 GMP suites online
- 1 large-scale suite in progress
- Broad European CMO network
- Flexible and mobile GMP units

**STRATEGIC PARTNERSHIPS**
- Development support
- Medical affairs expertise
- Commercial execution power

---

*As of September 30, 2020
## FOCUS AREA

### Prophylactic Vaccines
- Induction of antibody responses
- Induction of T-cell responses

### Oncology
- Induction of T-cell responses
- Induction of antibody responses
- Breaking of tolerance
- Activation of innate and adaptive immunity

### Protein Therapy
- Oncology
  - Use of the liver as a bioreactor
  - Convey controlled immunogenicity
- Rare Diseases
  - Ocular administration
  - Mucosal delivery
  - Other

## LEAD PROGRAM / COLLABORATION

<table>
<thead>
<tr>
<th>Application</th>
<th>Program/Collaboration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylactic Vaccines</strong></td>
<td>COVID-19 CVnCoV, Rabies CV7202</td>
</tr>
<tr>
<td><strong>Oncology</strong></td>
<td>Tumor-associated antigens, Shared neo-antigens, CV8102</td>
</tr>
<tr>
<td><strong>Protein Therapy</strong></td>
<td>Genmab collaboration, Harvard collaboration, Yale collaboration, CRISPR collaboration</td>
</tr>
</tbody>
</table>

## FORMULATION

<table>
<thead>
<tr>
<th>Application</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylactic Vaccines</strong></td>
<td>Lipid nano-particle</td>
</tr>
<tr>
<td><strong>Oncology</strong></td>
<td>Lipid nano-particle, Peptide based</td>
</tr>
<tr>
<td><strong>Protein Therapy</strong></td>
<td>Lipid nano-particle, Polymer based, Lipid nano-particle</td>
</tr>
</tbody>
</table>
CureVac Pipeline: A Diversified Portfolio

<table>
<thead>
<tr>
<th>AREA</th>
<th>PROGRAMS AND INDICATIONS</th>
<th>COLLABORATIONS</th>
<th>PRE-CLINICAL DISCOVERY</th>
<th>PRE-CLINICAL DEVELOPMENT</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROPHYLACTIC VACCINES</td>
<td>CVnCoV: COVID-19</td>
<td>CEP</td>
<td></td>
<td>(2)</td>
<td></td>
<td></td>
<td>(1)</td>
</tr>
<tr>
<td></td>
<td>CV7202: Rabies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lassa, Yellow Fever</td>
<td>CEP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respirational Syncytial Virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diverse projects (Rota, Malaria, Universal Influenza)</td>
<td>BILL &amp; MELINDA GATES FOUNDATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ONCOLOGY</td>
<td>CV8102: cMEL, ACC, SCC, HNSCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BI13618409 (CV9202): Non-Small Cell Lung Cancer</td>
<td>Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shared neo-antigen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumor Associated Antigens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTEIN THERAPY</td>
<td>Cas9 Gene-editing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung Respiratory Diseases</td>
<td>Yale</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic Antibodies</td>
<td>Genmab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) We have initiated a combined Phase 2b/3 clinical trial, called HERALD, for our COVID-19 vaccine candidate, CVnCoV
(2) CEPI early stage Phase 1 clinical trial funding

cMEL: Cutaneous melanoma; ACC: Adenoid cystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck
Unmodified mRNA: Differentiated Mode of Action, Mimics Natural Immunity

- Optimizing untranslated regions based on potent, tissue-specific regulatory elements
- Optimizations allow for increased translation efficiency and immunogenicity
- Maximizing ribosome interaction for increased protein expression enables low dose activity
Unique Mechanism of Action for Immunotherapy and Infectious Diseases

**UNIQUE MECHANISM OF ACTION**
- Unmodified, natural mRNA
- Inducing type I interferons
- Inducing B and T cell responses
- Activating innate immune system
- Inducing boostable memory responses

**PROPHYLACTIC VACCINES**
- Active at **low dose** in humans
- Enables **multivalent** vaccines
- Fast, **large-scale** GMP production
- Multiple product candidates

**CANCER VACCINES & IMMUNO-MODULATION**
- **Innate** and **adaptive** immune activation
- Key activation of **T cell responses**
- Demonstrated **breaking of tolerance**
- Multiple product candidates
2020 – Year of Corporate Transformation

<table>
<thead>
<tr>
<th>COVID-19 PROGRAM</th>
<th>BUSINESS EVOLUTION</th>
<th>FINANCIAL EXECUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rigorous pre-clinical candidate selection</td>
<td>Accelerated clinical development in Phase 1, 2, 3</td>
<td>Manufacturing optimization and scale-up</td>
</tr>
<tr>
<td></td>
<td>Growing talent base: &gt;500 employees</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management expertise expansion</td>
<td>Strategic partnership</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CVAC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Strong cash position: ~$1.61 billion*</td>
</tr>
</tbody>
</table>

*As of December 31, 2020, conversion rate €/$ 1.223

EC: European Commission
Our Core Mandate 2021: Deliver a Safe and Effective COVID-19 Vaccine

**Succeeding in the clinic**
- Expect to provide first efficacy data in late Q1/early Q2 2021
- Expect to apply for regulatory approval in Q2 2021

**Creating capacity**
- 3 in-house GMP certified suites
- 4th large-scale suite in progress
- Trans-European CMO network

**Delivering the vaccine**
- Partners for key operational, developmental & commercial support
- Cross-border and cross-institution collaborations
Clinical Development of COVID-19 Vaccine Candidate, CVnCoV

**DOSE ESCALATION TRIAL**
- 2-20µg, placebo controlled
- 280 participants, **fully recruited**
- Expected data update: **Q1 2021**

**DOSE CONFIRMATION TRIAL**
- 6µg / 12µg, placebo controlled
- 690 participants, **fully recruited**
- Expected first data: **Q1 2021**

**SAFETY AND EFFICACY TRIAL**
- 12µg, placebo controlled
- Exp. >37,000 participants, **recruiting**
- Expected interim data: **late Q1/early Q2 2021**
## Deliver on the Potential of the Curevac Technology to Create Sustainable Value

<table>
<thead>
<tr>
<th></th>
<th>Original Spike protein</th>
<th>Mutated Spike proteins</th>
<th>Combination vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt;-gen vaccines, CureVac’s CVnCoV</td>
<td>Collaboration and Services Agreement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;nd&lt;/sup&gt;-gen vaccines, Co-development</td>
<td>Co-Development Partnership</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Short-term value creation
- Government orders

### Mid- and long-term value creation
- GSK partnership and CureVac DACH commercial operations

---

SVB Leerink 10th Annual Global Healthcare Conference 2021

DACH: Germany, Austria, Switzerland
Execution Power Provided by Bayer’s Large-Pharma Infrastructure

Collaboration and Services Agreement
Announced January 7, 2021

- **Expertise and Infrastructure**
  Adding operational knowledge, broad international reach and regional access to support global supply of CureVac’s CVnCoV

- **Product Development Support**
  Adding muscle in areas such as clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance

- **Key Territory Operations**
  Adding country support for EU member states and beyond
  CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU

Financials

- **Service Agreement**
- **MAH:**
  - CureVac in the EU
  - Option for Bayer in other geographies

Operational expertise
Execution power
International reach
Co-Development Partnership

Announced July 20, 2020, extended on February 3, 2021

- Vaccine Development Expertise
  
  Joint development of 2nd generation mRNA vaccines including monovalent and multivalent approaches to address emerging variants in one vaccine
  
  Joint efforts to address new and future variants to stay one step ahead of the pandemic with resources to research, development and manufacturing
  
  Focus on developing post-pandemic vaccines

- Commercialization Roles

  GSK to be Marketing Authorization Holder with exclusive rights for development, manufacturing, and commercialization
  
  CureVac to retain three commercial areas: Germany, Austria, Switzerland

Financials

- Upfront: €75 m
- Milestone: €75 m
- Cost/profit split: 50:50
- MAH: GSK
At the Forefront of Science and Surveillance with the VTF of the UK Government

Research and Development Collaboration
Announced February 5, 2021

- Scientific Variant Assessment and Selection
  Assessing novel vaccines for SARS-CoV-2 variants and vaccine approaches against selected mutations
  Building on the VTF leading scientific expertise
  Mitigate the effects of the current pandemic, help manage and prepare for future outbreaks

- Clinical trial execution
  Clinical studies are expected to be undertaken in the UK towards securing marketing authorizations for jointly selected vaccines

- Manufacturing and distribution
  Technology transfer by CureVac
  Resulting vaccines expected to be manufactured and distributed in the UK and its overseas and dependent territories

Financials
- Each one carries own R&D costs
- UK to purchase 50m doses
- MAH: CureVac
CVnCoV Shelf Life Allows for Established Cold-Chain Distribution

-80°C → 5°C → 5°C → 5°C → Room temp.

- **5°C (41°F) SHELF LIFE OF AT LEAST 3 MONTHS* FOR 24 HOURS**

- Facilitated logistics for decentralized storage and large-scale vaccination efforts
- Expected positive impact on distribution, cost and waste compared to ultra-low cold chain requirements

---

*Stability studies for CVnCoV are ongoing and results may change materially*
Scaling-up Internal and External Manufacturing Capacities

<table>
<thead>
<tr>
<th>GMP I</th>
<th>GMP II</th>
<th>GMP III</th>
<th>European CMO network</th>
</tr>
</thead>
<tbody>
<tr>
<td>online</td>
<td>online</td>
<td>online</td>
<td></td>
</tr>
<tr>
<td>Phase I/II</td>
<td>Phase I/II</td>
<td>Phase III Initial market supply</td>
<td></td>
</tr>
</tbody>
</table>

- Highly experienced CMO partners for key manufacturing steps
- Flexible network to serve pandemic demand, mitigating supply chain risks
- Expected annual network output: up to 300m doses in 2021, up to 600m doses in 2022

GMP IV
- expected H2 2022
- Large-scale market supply

CMO: Contract manufacturing organization
RNA Printer™: Mobile Manufacturing Expected to Revolutionize GMP Process

Cloud based network
Rapid exchange of insights

GLOBAL HEALTH

PANDEMIC PREPAREDNESS in hospitals in outbreak regions
- Containing an outbreak directly at its origin

HEALTHCARE

CUSTOMIZED, POINT OF CARE mRNA therapeutics
- Expected to rapidly provide therapeutics tailored to patients’ needs

RESEARCH

CLINICAL DEVELOPMENT ACCELERATION at lower costs
- Realizing different constructs and supplying studies onsite
Key Agreement with European Commission

Delivering up to 405 million doses of CVnCoV to European member states

- Agreement for 225m doses and an additional 180m dose option
- Upfront payment expected to mitigate project costs and help to de-risk production before regulatory approval
- Leveraging in-house manufacturing as well as integrated European manufacturing network
Our Financial Strength Enables the Company Transformation

Nasdaq listing: ~€193 million

~€252 million
Grant of the German Federal Ministry of Education and Research

~€150 million
GSK

~€300 million
KfW

Private Round: ~€560 million

Cumulative Investments ~€110 million

€50 million
1st tranche drawn of the European Investment Bank (EIB)

NEW: ~$517.5m
Aggregated gross proceeds from public offering closed February 2021

*As of December 31, 2020, conversion rate €/$ 1.223
Thank you for your interest